DISSEMINATED VISCERAL FUSARIOSIS TREATED WITH AMPHOTERICIN-B-PHOSPHOLIPID COMPLEX

被引：15

作者：

ENGELHARD, D

ELDOR, A

POLACHECK, I

HARDAN, I

BENYEHUDA, D

AMSELEM, S

SALKIN, IF

LOPEZBERESTEIN, G

SACKS, T

RACHMILEWITZ, EA

BARENHOLZ, Y

机构：

[1] Departments of Clinical Microbiology, M.D. Anderson Cancer Center, University of Texas, Houston, TX

[2] Departments of Hematology, Hadassah University Hospital M.D. Anderson Cancer Center, University of Texas, Houston, TX

[3] Department of Biochemistry, Hebrew University-Hadassah Medical School, Jerusalem

[4] New York State Department of Health, Wadsworth Center for Laboratories and Research, Albany, NY

[5] Department of Clinical Immunology and Biological Therapy, M.D. Anderson Cancer Center, University of Texas, Houston, TX

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 9卷 / 4-5期

关键词：

FUNGAL INFECTION; FUSARIUM; AMPHOTERICIN-B; ANTIFUNGAL; FUSARIOSIS; AMPHOTERICIN-B CHOLESTERYL SULFATE COMPLEX (AMPHOCIL(TM)); AMPHOTERICIN-B-LIPID COMPLEX;

D O I：

10.3109/10428199309148539

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fusariosis, a rare infectious disease of the immunocompromised host, is relatively resistant to amphotericin B (AmB) or other antifungal agents. We describe a 5-year follow-up of a 40 year old woman with T-type acute lymphoblastic leukemia who following chemotherapy developed prolonged high fever, chills, night sweats, and severe weakness. Liver function tests were impaired and abdominal computerized tomography (CT) showed multiple lesions in the liver and abnormal structure of the spleen. A laparotomy revealed multiple granulomas containing Fusarium sp. in the liver, and the spleen was heavily infiltrated by the same fungus. The patient failed to respond to the conventional AmB dosage form (Fungizone) even after a total dose of 3.0 g was given, and developed significant renal impairment. AmB was complexed (in a mole ratio of 1:16) with a mixture of the phospholipids dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (mixed in 7:3 mole ratio). The resulting drug complex, AmB-PLC, was then administered (1-4 mg/kg/day, total dose 4.2 g) and subsequently the patient was cured of all symptoms of fusariosis. There were only mild side effects and no nephrotoxicity was evident. On the contrary, marked improvement of the renal function tests occurred during AmB-PLC treatment. Eight months later, she developed a spinal lesion with dense consistency in L5 and S1, and after receiving another course of AmB-PLC (3.1 g) she recovered completely. In a 2 year follow-up period the patient had no further relapse of the fungal disease. Subsequent chemotheraphy given for relapse of the leukemia was followed by a new fungal infection, which was treated with AmB-cholesteryl sulfate complex (Amphocil(TM))*. The patient received 13.0 g Amb as Amphocil and fully recovered from the fungal infection. This case report suggests that when Fungizone is nephrotoxic and does not permit efficacious antifungal treatment, AmB complexed with suitable lipids may be safe efficacious therapy.

引用

页码：385 / 392

页数：8

共 30 条

[1]

Anaissie E., Kantarjian H., Jones P., Barlogie B., Luna M., Lopez-Berestein G., Bodey G.P., Fusarium. A newly recognized fungal pathogen in immunosuppressed patients, Cancer, 57, pp. 2141-2145, (1986)

[2]

Minor R.L., Pfaller M.A., Bingrich R.D., Burns L.J., Disseminated Fusarium infections in patients following bone marrow transplantation, Bone Marrow Transplant, 4, pp. 653-658, (1989)

[3]

Richardson S.E., Bannatyne R.M., Summerbell R.C., Milliken J., Gold R., Weitzman S.S., Disseminated fusarial infection in the immunocompromised host, Rev. Infect. Dis., 10, pp. 1171-1181, (1988)

[4]

Venditti M., Micozzi A., Gentile G., Palomellr L., Morace G., Bianco P., Avvisati G., Papa G., Martino P., Invasive Fusarium solani infections in patients with acute leukemia, Rev. Infect. Dis., 10, pp. 653-660, (1988)

[5]

Anaissie E., Kantarjian H., Ro J., Hopfer R., Rolston K., Fainstein V., Bodey G., The emerging role ofinfections in patients with cancer, Medicine (Baltimore). Fusarium, 67, pp. 77-83, (1988)

[6]

Summerbell R.C., Richardson S.E., Kane J., Fusarium proli as an agent of disseminated infection in an immunosuppressed patient, J. Clin. Microbiol, 26, pp. 82-87, (1988)

[7]

Blazar B.R., Hurd D.D., Snover D.C., Alexander J.W., McGlave P.B., Invasive Fusarium infections in bone marrow transplant recipients, Am. J. Med., 77, pp. 645-651, (1984)

[8]

Merz W.G., Karp J.E., Hoagland M., Jett-Goheen M., Junkins J.M., Hood A.F., Diagnosis and successful treatment of fusariosis in the compromised host, J. Infect. Dis., 158, pp. 1046-1055, (1988)

[9]

Kiehn T.E., Nelson P.A., Bernard E.M., Edwards F.F., Koziner B., Armstrong D., Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytic lymphoma, J. Clin. Microbiol, 21, pp. 501-504, (1985)

[10]

Lopez-Berestein G., Fainstein V., Hopfer R., Et al., Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer. A preliminary study, J. Infect. Dis., 151, pp. 704-710, (1985)

← 1 2 3 →